- Home
- CLLS vs EIC Comparison
CLLS vs EIC Comparison
Compare CLLS & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- EIC
- Stock Information
- Founded
- CLLS 1999
- EIC N/A
- Country
- CLLS France
- EIC United States
- Employees
- CLLS N/A
- EIC N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- CLLS Health Care
- EIC Finance
- Exchange
- CLLS Nasdaq
- EIC Nasdaq
- Market Cap
- CLLS 143.4M
- EIC 339.0M
- IPO Year
- CLLS 2007
- EIC 2019
- Fundamental
- Price
- CLLS $1.51
- EIC $13.64
- Analyst Decision
- CLLS Buy
- EIC Strong Buy
- Analyst Count
- CLLS 1
- EIC 1
- Target Price
- CLLS $4.00
- EIC $17.50
- AVG Volume (30 Days)
- CLLS 50.1K
- EIC 343.8K
- Earning Date
- CLLS 08-05-2025
- EIC 08-05-2025
- Dividend Yield
- CLLS N/A
- EIC 17.57%
- EPS Growth
- CLLS N/A
- EIC N/A
- EPS
- CLLS N/A
- EIC 0.55
- Revenue
- CLLS $54,747,000.00
- EIC $51,224,692.00
- Revenue This Year
- CLLS $48.52
- EIC $42.67
- Revenue Next Year
- CLLS $5.17
- EIC $29.16
- P/E Ratio
- CLLS N/A
- EIC $24.76
- Revenue Growth
- CLLS 351.26
- EIC 68.61
- 52 Week Low
- CLLS $1.10
- EIC $12.63
- 52 Week High
- CLLS $2.43
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- CLLS 54.99
- EIC 48.31
- Support Level
- CLLS $1.40
- EIC $13.32
- Resistance Level
- CLLS $1.49
- EIC $13.45
- Average True Range (ATR)
- CLLS 0.08
- EIC 0.19
- MACD
- CLLS 0.01
- EIC 0.07
- Stochastic Oscillator
- CLLS 87.87
- EIC 93.33
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.